Teemu Junttila

Senior Scientist, Translational Oncology
Teemu Junttila, Genentech
Dr. Junttila joined Genentech in 2006. His early work focused on characterizing the impact and mechanism of action of Herceptin (trastuzumab) and Kadcyla (ado-trastuzumab emtansine; T-DM1), in addition to PI3K inhibitors in the treatment of breast cancer. Notably, this work unveiled a previously unknown mechanism of action for Herceptin that was key for understanding the biological underpinning of Perjeta and Herceptin combination synergy (now in clinical use). Currently his research is focused on developing Genentechs T cell dependent bispecific (TDB) antibodies and he is responsible for multiple CD3-bispecific molecules in various stages, ranging from early stage research to clinical development.


No data was found